Pfizer to Acquire CSL Animal Health Business

16-Dec-2003
Pfizer Animal Health has agreed to acquire CSL Animal Health, a division of CSL Limited (Melbourne, Australia), for $126.2 million in cash, Pfizer announced today. [Please note that all financials are in U.S. dollars.] The acquisition will enhance Pfizer Animal Health's presence in the Australian marketplace with CSL's well-received line of livestock and companion animal vaccines, its highly professional sales force, and its advanced manufacturing facilities in Australia and New Zealand. CSL Animal Health has also built a strong, productive research initiative in Australia. With the largest annual investment in animal health research in the industry, Pfizer expects to further develop CSL's R & D activity, which, to date, has yielded advances including the broadest range of sheep vaccines and other innovative biological products. In 2002, CSL Animal Health sales increased 6 percent to $46 million. Through the third quarter of 2003, Pfizer Animal Health-which combined with Pharmacia Animal Health in April of this year-reported sales of $1.09 billion.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!